Video

David W. Goodman, MD: APSARD 2021 Bringing Together International ADHD Research

Author(s):

The virtual conference will feature researchers from the US, Germany, Japan, and more.

The collaboration of international researchers during the American Professional Society of ADHD and Related Disorders (APSARD) 2021 Annual Conference could have a profound impact on attention deficit/hyperactivity disorder treatment and care across the globe.

Despite not being able to host an in-person live meeting due to the coronavirus disease 2019 (COVID-19) pandemic, APSARD has amassed a list of investigators presenting new studies and plenary speeches about a wide range of ADHD and psychiatry topics.

However, the virtual format enables researchers from Germany, Japan, and other far reaching places to contribute research and insight during the three-day conference without the additional expense of travel.

In an interview with HCPLive®, David W. Goodman, MD, FAPA, assistant professor of psychiatry and behavioral sciences at Johns Hopkins School of Medicine, explained how difficult it is to get major contributors from across the globe to present data during meetings and how it came out during APSARD.

Goodman, who serves as co-chair on APSARD’s education committee, previewed the meeting and explained how the virtual format will allow for more international input.

Just as important sharing data will be, Goodman said it is also important for the attendees to get an idea how ADHD is researched and treated in different countries.

Related Videos
| Image Credit: X
Ahmad Masri, MD, MS | Credit: Oregon Health and Science University
Ahmad Masri, MD, MS | Credit: Oregon Health and Science University
Stephen Nicholls, MBBS, PhD | Credit: Monash University
Marianna Fontana, MD, PhD: Nex-Z Shows Promise in ATTR-CM Phase 1 Trial | Image Credit: Radcliffe Cardiology
Zerlasiran Achieves Durable Lp(a) Reductions at 60 Weeks, with Stephen J. Nicholls, MD, PhD | Image Credit: Monash University
Gaith Noaiseh, MD: Nipocalimab Improves Disease Measures, Reduces Autoantibodies in Sjogren’s
A. Sidney Barritt, MD | Credit: UNC School of Medicine
Safety Data on Dupilumab, Ensifentrine for COPD, with MeiLan Han, MD
© 2024 MJH Life Sciences

All rights reserved.